For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250918:nRSR7811Za&default-theme=true
RNS Number : 7811Z Feedback PLC 18 September 2025
Feedback plc
Annual Report and Notice of Annual General Meeting
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical
infrastructure specialist, announces that its Annual Report and Financial
Statements for the year ended 31 May 2025, together with the Notice convening
the Company's Annual General Meeting ("AGM"), are now available on the
Company's website at: https://feedbackmedical.com/investors. Hard copies of
the 2025 Annual Report and Financial Statements and Notice of AGM have also
been posted to shareholders today.
The AGM will be held at Temple Chambers, 3-7 Temple Avenue, London, EC4Y 0DT,
on Monday 13 October 2025 at 9:30 a.m.
AGM Broadcast
In addition to attending in person, shareholders will have the option to
follow the proceedings of the AGM online. Shareholders interested in attending
online are requested to register their remote attendance with Walbrook PR, the
Company's Investor & Public Relations adviser, by
emailing feedbackplc@walbrookpr.com
(mailto:feedbackplc@walbrookpr.com?subject=FDBK%20-%20AGM%20Videoconference) .
This will be a closed forum and shareholders wishing to attend will be
required to supply proof of their shareholding or a letter of corporate
representation. Upon successful registration, a link will be emailed to
attendees wishing to join online up to 48 hours before the AGM.
There will be no corporate presentation. Specific questions may be lodged by
email to Walbrook PR at feedbackplc@walbrookpr.com
(mailto:feedbackplc@walbrookpr.com?subject=FDBK%20-%20AGM%20Videoconference)
and the Directors will endeavour to answer them during the question and
answer part of the AGM. Shareholders will be able to view the business of the
AGM only and will not be able to use this facility to vote, raise points or
issues, ask questions or table resolutions.
-Ends-
Enquiries:
Feedback plc +44 (0) 20 3997 7634
Tom Oakley, CEO IR@fbk.com (mailto:IR@fbk.com)
Anesh Patel, CFO
Panmure Liberum Limited (NOMAD and Broker) +44 (0)20 7886 2500
Emma Earl/ Mark Rogers (Corporate Finance)
Rupert Dearden (Corporate Broking)
Walbrook PR Ltd; Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
(mailto:feedbackplc@walbrookpr.com)
Nick Rome/Joe Walker 07748 325 236 or 07407 020 470
About Feedback plc
Feedback plc liberates the data and knowledge from multiple healthcare IT
systems and delivers better workflow to enable clinicians to communicate,
collaborate and provide the best healthcare for their patients. We connect
care settings with diagnostic and other relevant data to drive better, faster,
safer decision that improve outcomes for patients.
By linking different clinical systems together into a seamless view of the
patient, we can streamline patient pathways and deliver a digital health and
diagnostics record across multiple care providers.
Bleepa® is our communication and collaboration platform that displays
clinical results at a certified and regulated quality, which enables
multi-disciplinary team working and diagnostic-enhanced advice and guidance.
CareLocker® is our patient-facing platform that gives patients access and
control over their diagnostic and other clinical data.
The Company has a number of growth opportunities domestically and
internationally across a range of public and private healthcare markets
including the NHS. Our highly scalable software-as-a-service (SaaS) based
model is expected to provide increasing levels of revenue visibility as the
Company grows its customer base.
https://feedbackmedical.com/
(https://urldefense.proofpoint.com/v2/url?u=https-3A__feedbackmedical.com_&d=DwMGaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=lwwmT1lSfgELFLcwvlJQ2ZXDKcVbkQyitKwD17cChBQ&m=oBFM-ht-5vvdSXufzCuQmLfPWIaMcFGcjFY8Tl7Z-dsq0iW8FbXgExGw9gLP3va-&s=kayb21_5OhwDnHa1pJnJQjB1999VQgQynAFl7rWXro4&e=)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NOAVDLFFEKLFBBZ